Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic Equivalence of Fluticasone/Salmeterol in Asthma
NCT05664061Phase 3Unknown
- Sponsor
- Respirent Pharmaceuticals Co. Ltd.
- Start
- Jan 2023
- Primary completion
- Jul 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of fluticasone propionate nasal spray, salmeterol in asthma, sponsored by Respirent Pharmaceuticals Co. Ltd.. Status: unknown.
02
Drugs
fluticasone propionate nasal spraysalmeterol
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05664061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05664061.